AQR Capital Management
LUCD icon

AQR Capital Management’s Lucid Diagnostics LUCD Stock Holding History

AQR Capital Management’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$270K Buy
234,769
+153,208
+188% +$195K ﹤0.01% 3458
2025
Q4 		$88.9K Buy
81,561
+865
+1% +$967 ﹤0.01% 3471
2025
Q3 		$81.5K Buy
+80,696
New +$88.1K ﹤0.01% 3386

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

AQR Capital Management's LUCD Position: Q1 2026 in Review

AQR Capital Management increased its Lucid Diagnostics (LUCD) stake by 188% in Q1 2026, buying an estimated $195K and bringing the position to 234,769 shares worth $270K. The position accounts for ﹤0.01% of the portfolio, ranked #3458.

AQR Capital Management first reported a position in LUCD in Q3 2025 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • AQR Capital Management held 234,769 shares of Lucid Diagnostics worth $270K as of Q1 2026.
  • AQR Capital Management bought 153,208 Lucid Diagnostics shares in Q1 2026, an estimated $195K.
  • Lucid Diagnostics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3458 holding.
  • AQR Capital Management first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.